Boston, MA -- (SBWIRE) -- 03/09/2017 -- Global Markets Direct's, 'NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Get More Details on this Report and a Full Table of Contents at NT 3 Growth Factor Receptor - Pipeline Review, H2 2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Report Scope

-The report provides a snapshot of the global therapeutic landscape for NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
-The report reviews NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
-The report assesses NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics

Reasons to Get this Report

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Companies Mentioned in this Report: Array BioPharma Inc, AstraZeneca Plc, Daiichi Sankyo Company Ltd, Ignyta Inc, Loxo Oncology, Inc., Netris Pharma SAS, PharmatrophiX Inc, SOM Biotech SL

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-BDNF/NT 3 Growth Factors Receptor - Pipeline Review, H2 2016
-Fibroblast Growth Factor Receptor 3 - Pipeline Review, H2 2016
-NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H1 2016
-Fibroblast Growth Factor Receptor 1 - Pipeline Review, H2 2016
-Fibroblast Growth Factor Receptor 2 - Pipeline Review, H2 2016